98%
921
2 minutes
20
The issue of bacterial infections in COVID-19 patients has received increasing attention. Scant data are available on the impact of bacterial superinfection and antibiotic administration on the outcome of hospitalized COVID-19 patients. We conducted a literature review from 1 January 2022 to 31 March 2024 to assess the current burden of bacterial infection and the evidence for antibiotic use in hospitalized COVID-19 patients. Published articles providing data on antibiotic use in COVID-19 patients were identified through computerized literature searches with the search terms [(antibiotic) AND (COVID-19)] or [(antibiotic treatment) AND (COVID-19)]. PubMed and SCOPUS databases were searched from 1 January 2022 to 31 March 2024. No attempt was made to obtain information about unpublished studies. English language restriction was applied. The quality of the included studies was evaluated by the tool recommended by the Joanna Briggs Institute. Both quantitative and qualitative information were summarized by means of textual descriptions. Five hundred fifty-one studies were identified, and twenty-nine studies were included in this systematic review. Of the 29 included studies, 18 studies were on the prevalence of bacterial infection and antibiotic use in hospitalized COVID-19 patients; 4 studies reported on the efficacy of early antibiotic use in COVID-19; 4 studies were on the use of sepsis biomarkers to improve antibiotic use; 3 studies were on the efficacy of antimicrobial stewardship programs and predictive models among COVID-19-hospitalized patients. The quality of included studies was high in 35% and medium in 62%. High rates of hospital-acquired infections were reported among COVID-19 patients, ranging between 7.5 and 37.7%. A high antibiotic resistance rate was reported among COVID-19 patients developing hospital-acquired infections, with a high in-hospital mortality rate. The studies evaluating multi-faceted antimicrobial stewardship interventions reported efficacy in decreasing antibiotic consumption and lower in-hospital mortality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200443 | PMC |
http://dx.doi.org/10.3390/antibiotics13060545 | DOI Listing |
JMIR Hum Factors
September 2025
Villa Beretta Rehabilitation Center, Costa Masnaga, Italy.
Background: Telerehabilitation is a promising solution to provide continuity of care. Most existing telerehabilitation platforms focus on rehabilitating upper limbs, balance, and cognitive training, but exercises improving cardiovascular fitness are often neglected.
Objective: The objective of this study is to evaluate the acceptability and feasibility of a telerehabilitation intervention combining cognitive and aerobic exercises.
JMIR Public Health Surveill
September 2025
Center of Indigenous Health Care, Department of Community Health, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
Background: The COVID-19 pandemic has devastated economies and strained health care systems worldwide. Vaccination is crucial for outbreak control, but disparities persist between and within countries. In Taiwan, certain indigenous regions show lower vaccination rates, prompting comprehensive inquiries.
View Article and Find Full Text PDFObjective: .Aim: To investigate the pathomorphological changes in the terminal chorionic villi during COVID-19 in pregnant women.
Patients And Methods: Materials and Methods: A total of 123 placentas were studied in cases of live term births (groups І) and antenatal asphyxia (groups ІІ).
Pol Merkur Lekarski
September 2025
FACULTY OF NURSING, UNIVERSITY OF KUFA, KUFA, IRAQ.
Objective: Aim: To evaluate clinical applicability of immune mediator's interleukin-16, immunoglobulin E along with eosinophil count in diagnosing COVID-19 and determining its severity.
Patients And Methods: Materials and Methods: Cross-sectional case-control study was conducted at Al-Najaf General Hospital, Najaf, Iraq between March and August 2024. 120 participants: 60 confirmed COVID-19 cases and 60 healthy controls which matched cases in terms of age and sex.
Crit Care Sci
September 2025
Universitätsklinikum Carl Gustav Carus - Dresden, Sachsen, Germany.
The PROtective VEntilation (PROVE) Network is a globally-recognized collaborative research group dedicated to advancing research, education, and collaboration in the field of mechanical ventilation. Established to address critical questions in intraoperative and intensive care ventilation, the network focuses on improving outcomes for patients undergoing mechanical ventilation in diverse settings, including operating rooms, intensive care units, burn units, and resource-limited environments in low- and middle-income countries. The PROVE Network is committed to generating high-quality evidence through a comprehensive portfolio of investigations, including randomized clinical trials, observational research, and meta-analyses.
View Article and Find Full Text PDF